General
Preferred name
ZANAMIVIR
Synonyms
GG167 ()
Relenza ()
GG167,GR 121167X ()
ZANAMIVIR HYDRATE ()
GG-167 ()
GR-121167X ()
GR 121167X ()
GR-121167 ()
J1.917.534K ()
Dectova ()
D01937 ()
Zanamivir-13C,15N2 (hydrate) ()
P&D ID
PD009965
CAS
139110-80-8
Tags
available
drug
Approved by
FDA
EMA
First approval
2019
1999
Drug indication
influenza
infection
Influenza virus infection
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE
It is excreted unchanged in the urine with excretion of a single dose completed within 24 hours.; Unabsorbed drug is excreted in the feces.Zanamivir is renally excreted as unchanged drug.
DESCRIPTION
Zanamivir (GG167) is a sialic acid-analogue that is used as an antiviral drug. Mechanistcally it inhibits the neuraminidases of both influenza A and B, enzymes that cleave sialic acid residues from host membrane-bound glycoproteins to increase both infection and release of new virus particles from the infected respiratory epithelium. also belongs to this class of anti-influenza drugs.
A combination of zanamivir and oseltamivir is reported to inhibit mammalian neuraminidase 1 (NEU1) which has the effect of reducing neutrophil overactivation in response to severe viral infection . It is proposed that pharmacological modulation of human NEU1 may represent a novel intervention to dampen neutrophil dysfunction (and the associated tissue damage) during severe infections, as observed in COVID-19. (GtoPdb)
A combination of zanamivir and oseltamivir is reported to inhibit mammalian neuraminidase 1 (NEU1) which has the effect of reducing neutrophil overactivation in response to severe viral infection . It is proposed that pharmacological modulation of human NEU1 may represent a novel intervention to dampen neutrophil dysfunction (and the associated tissue damage) during severe infections, as observed in COVID-19. (GtoPdb)
PRICE
53
DESCRIPTION
Potent irreversible proteasome inhibitor; active in vivo
(Tocris Bioactive Compound Library)
DESCRIPTION
Zanamivir (GG167) is a guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
8
Compound Sets
25
AdooQ Bioactive Compound Library
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
59
Molecular Weight
332.13
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
8
Rotatable Bonds
6
Ring Count
1
Aromatic Ring Count
0
cLogP
-3.58
TPSA
198.22
Fraction CSP3
0.58
Chiral centers
5.0
Largest ring
6.0
QED
0.18
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
antibiotic
Influenza A
Influenza B
Influenza Virus
NEU2
Influenza Virus,Neuraminidase
Primary Target
Other Hydrolases
MOA
Inhibitor
inhibitor of neuraminidase and Sialidase
neuraminidase inhibitor
Member status
member
Indication
influenza A virus infection
Biosynthetic Origin
Carbohydrate (Aminoglycoside)
Therapeutic Indication
Antiviral
Pathway
Microbiology/virology
Anti-infection
Therapeutic Class
Antiviral Agents
Source data
